Duration of rheumatoid arthritis and the risk of developing interstitial lung disease

Michael P. Mohning, Isabelle Amigues, M. Kristen Demoruelle, Evans R. Fernández Pérez, Tristan J. Huie, Rebecca K. Keith, Amy L. Olson, Zulma X. Yunt, Jonathan H. Chung, Stephen Hobbs, Jeffrey J. Swigris, Joshua J. Solomon

Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020
Journal Issue: January
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Michael P. Mohning, Isabelle Amigues, M. Kristen Demoruelle, Evans R. Fernández Pérez, Tristan J. Huie, Rebecca K. Keith, Amy L. Olson, Zulma X. Yunt, Jonathan H. Chung, Stephen Hobbs, Jeffrey J. Swigris, Joshua J. Solomon. Duration of rheumatoid arthritis and the risk of developing interstitial lung disease. ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Risk factors of interstitial lung diseases in patients with rheumatoid arthritis.
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019

Mortality and clinical features in rheumatoid arthritis and interstitial lung disease
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017

Interstitial lung disease in patients with rheumatoid arthritis
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008

Predicting outcomes in rheumatoid arthritis related interstitial lung disease
Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018
Year: 2019



Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2016; 47: 588-596
Year: 2016



Methotrexate and rheumatoid arthritis associated interstitial lung disease
Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020
Year: 2021



Characteristics and predictors of outcome in rheumatoid arthritis related ILD
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013

Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new
Source: Breathe, 16 (4) 1514; 10.1183/20734735.0223-2020
Year: 2020



Rituximab improves interstitial lung disease in rheumatoid arthritis patients
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017

Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis
Source: Annual Congress 2004 - Fibrosing lung diseases
Year: 2004


Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis
Source: Eur Respir J 2002; 20: Suppl. 38, 587s
Year: 2002

Analysis of lung diseases associated with rheumatoid arthritis
Source: Eur Respir J 2006; 28: Suppl. 50, 307s
Year: 2006

Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2015 – Connective tissue disorders
Year: 2015

Are smoking and COPD associated with ILD onset in rheumatoid arthritis?
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


Pulmonary disease associated with rheumatoid arthritis
Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Year: 2021

The lung in rheumatoid arthritis: drugs versus underlying disease
Source: Annual Congress 2009 - Lung disease in rheumatoid arthritis treated with tumour necrosis factor inhibitors: a pulmonary perspective
Year: 2009


Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016


Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016

The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013


Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019